Abstract：【Objective】To investigate the efficacy and safety of Budesonide-Formoterol inhalation aerosol in treating high-risk acute exacerbations of chronic obstructive pulmonary disease (COPD).【Methods】A total of 160 patients with high-risk acute exacerbations of COPD were randomly divided into the observation group (treated with Budesonide-Formoterol inhalation aerosol) and the control group (treated with Indacaterol-Glycopyrronium inhalation powder capsules), with 80 cases in each group. The differences in pulmonary function indicators, blood gas indicators, COPD assessment test (CAT) scores, modified Medical Research Council (mMRC) dyspnea scale scores, exercise endurance [six-minute walk distance (6MWD)] and quality of life (SGRQ) scores before treatment, and at 3 months and 6 months after treatment were compared between the two groups.【Results】 After 3 and 6 months of treatment, the pulmonary function indicators and blood gas indicators of the observation group were significantly better than those of the control group (P<0.05). The mMRC, CAT, and respiratory symptom scores in the SGRQ scale of the observation group were lower than those of the control group (P<0.05), and the 6MWD was higher than that of the control group (P<0.05). However, there was no statistically significant difference in daily activities, disease symptoms, and total scores on the SGRQ scale between the two groups (P>0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 Budesonide-Formoterol inhalation aerosol is effective in treating high-risk acute exacerbations of COPD and it does not increase the incidence of adverse drug reactions.
[1] HALPIN D M G, CRINER G J, PAPI A, et al. Global Initiative for the diagnosis, management, and prevention of chronic obstructive lung disease:the 2020 GOLD science committee report on COVID-19 & COPD[J].Am J Respir Crit Care Med,2021,203(1):24-36.
[2] HURST J R, VESTBO J, ANZUETO A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease[J].N Engl J Med,2010,363(12):1128-1138.
[3] KLAUS F RABE F J M G, BALLAL S, MCLAREN J, et al.Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD[J].N Engl J Med,2020,383(1):35-48.
[4] MALERBA M, NARDIN M, SANTINI G, et al. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD:the current evidence base and future prospects[J].Ther Adv Respir Dis,2018,12(2):102-104.
[5] GARY T FERGUSON K F R F, WANG C, ICHINOSE M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS):a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial[J].Lancet Respir Med,2018,6(10):747-758.
[6] LIU Y, SHI H, SUN X, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD:a meta-analysis[J].Eur J Intern Med,2014,25(5):491-495.
[7] 姚剑坤, 李翠君, 欧阳细瑜, 等. 布地格福吸入气雾剂联合肺康复训练对中重度慢阻肺患者的影响[J].中国实用医药, 2022,17(6):29-32.
[8] ROJAS-REYES M X, MORALES O M G, DENNIS R J, et al. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease[J].Cochrane Database Syst Rev,2016(6):D8532.
[9] 范晓艳. 布地格福吸入气雾剂对慢性阻塞性肺疾病急性加重期患者的疗效分析[J].中国药物与临床, 2021,21(24):3994-3997.
[10] 张妍琦, 李鑫, 孙璐, 等. 布地格福吸入气雾剂治疗中、重度支气管哮喘患者的临床研究[J].中国临床药理学杂志, 2022,38(1):3-5.
[11] 郑笑红. 布地格福吸入气雾剂治疗重度慢性阻塞性肺疾病的效果研究[J].中外医学研究, 2023,21(9):13-16.
[12] 孟现玲, 何玉廷, 毛若琳, 等. 圣乔治呼吸问卷、CAT及mMRC评分在慢性阻塞性肺病中的应用[J].复旦学报(医学版), 2022,49(6):862-868.
[13] HANANIA N A, SETHI S, KOLTUN A, et al. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD[J].Int J Chron Obstruct Pulmon Dis,2019,14:117-127.
[14] BRAVE H, MACLOUGHLIN R. State of the art review of cell therapy in the treatment of lung disease, and the potential for aerosol delivery[J].Int J Mol Sci,2020,21(17):6435.
2024, Vol. 41 
